Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Altimmune, Inc.
Report date January 31, 2026 · Filed February 02, 2026
Section 16 reporting ended · disclosed 2026-02-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 70,107 |
Reported balance
After 2026-01-31 transaction · row 1
1 source rowRow 1 · 2026-01-31 · Grant · Acquired 4,571 · Balance 70,107 F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2026 Filed Feb 2, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 4,571 | $3.07 | $14,032.97 |
DisclosureSEC source: 0001960780-26-000008 · form4-02022026_040201.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,107 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 15,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001960780-26-000006 · form4-01292026_040101.xml · derivative · entry 3 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,550 Underlying: Common Stock, par value $0.0001 · 15,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 4,229 | $6.18 | $26,135.22 |
DisclosureSEC source: 0001960780-26-000006 · form4-01292026_040101.xml · nonDerivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,536 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 15,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001960780-26-000006 · form4-01292026_040101.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001960780-26-000004 · form4-01272026_070101.xml · derivative · entry 3 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,200 Underlying: Common Stock, par value $0.0001 · 14,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,855 | $5.50 | $21,202.50 |
DisclosureSEC source: 0001960780-26-000004 · form4-01272026_070101.xml · nonDerivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,915 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001960780-26-000004 · form4-01272026_070101.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001960780-26-000002 · form4-01052026_040114.xml · derivative · entry 3 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock, par value $0.0001 · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: RSUs become vested and released over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: RSUs become vested and released over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,475 | $3.61 | $8,934.75 |
DisclosureSEC source: 0001960780-26-000002 · form4-01052026_040114.xml · nonDerivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,170 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001960780-26-000002 · form4-01052026_040114.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 20:06 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,368 | $3.14 | $4,295.52 |
DisclosureSEC source: 0001104659-25-073629 · tm2522384-3_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,270 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:45 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 2,614 | $5.18 | $13,540.52 |
DisclosureSEC source: 0001104659-25-008771 · tm255357-2_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,902 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2024 through January 31, 2025. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 1, 2024. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 63,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006843 · tm254755-3_4seq1.xml · derivative · entry 5 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,400 Underlying: Common Stock, par value $0.0001 · 63,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 183,600 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006843 · tm254755-3_4seq1.xml · derivative · entry 4 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,600 Underlying: Common Stock, par value $0.0001 · 183,600 shares Expires 2035-01-27 F4 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and released on January 27, 2026 and the remaining 75% of the shares underlying the option become vested and released in substantially equal monthly installments over the 36 months following January 27, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006843 · tm254755-3_4seq1.xml · derivative · entry 3 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Stock, par value $0.0001 · 14,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,862 | $6.98 | $26,956.76 |
DisclosureSEC source: 0001104659-25-006843 · tm254755-3_4seq1.xml · nonDerivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,288 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006843 · tm254755-3_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:40 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000836 · tm251877-1_4seq1.xml · derivative · entry 3 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock, par value $0.0001 · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested and released over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested and released over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:40 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,485 | $7.21 | $17,916.85 |
DisclosureSEC source: 0001104659-25-000836 · tm251877-1_4seq1.xml · nonDerivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,550 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:40 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000836 · tm251877-1_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 21:43 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 917 | $5.41 | $4,960.97 |
DisclosureSEC source: 0001104659-24-084993 · tm2420669-2_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,660 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2024 through July 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2024. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 5,030 | $2.69 | $13,530.70 |
DisclosureSEC source: 0001104659-24-009542 · tm244961-4_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,743 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. F3 · balance_after: The Issuer withheld 2,494 shares to cover taxes associated with the vesting of RSU on January 1, 2024 instead of the 2,503 shares reported as withheld on the individual's Form 4 filed on January 4, 2024. The updated total is reflective of the foregoing correction. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:32 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 58,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007862 · tm244341-4_4seq1.xml · derivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,400 Underlying: Common Stock, par value $0.0001 · 58,400 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:32 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 163,200 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001104659-24-007862 · tm244341-4_4seq1.xml · derivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,200 Underlying: Common Stock, par value $0.0001 · 163,200 shares Expires 2034-01-25 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001463 · tm242084-1_4seq1.xml · derivative · entry 3 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock, par value $0.0001 · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,503 | $11.25 | $28,158.75 |
DisclosureSEC source: 0001104659-24-001463 · tm242084-1_4seq1.xml · nonDerivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,704 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001463 · tm242084-1_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:43 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,832 | $2.81 | $5,147.92 |
DisclosureSEC source: 0001104659-23-086899 · tm2322669-1_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,832 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2023 through July 31, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:06 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-000836 · tm231429-2_4seq1.xml · derivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock, par value $0.0001 · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:06 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 125,000 | $0.00 Strike: $15.63 | $0.00 |
DisclosureSEC source: 0001104659-23-000836 · tm231429-2_4seq1.xml · derivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock, par value $0.0001 · 125,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.